Advances in Therapy

Advances in Therapy is a monthly rapid-publication journal published by Springer Healthcare, founded in 1984 and long part of the Adis portfolio, that carries clinical, observational and health outcomes research across every therapeutic area for hospital clinicians and researchers, with a 2025 Journal Impact Factor of 4.7《治疗进展》（Advances in Therapy）是（Springer Healthcare）出版的月刊快出版期刊，1984 年创刊并长期隶属（Adis）系列，面向医院临床医生与研究者，覆盖各治疗领域的临床、观察性与健康结局研究，2025 年影响因子为 4.7

Scope

• It publishes clinical research at all phases of development, together with observational, real-world and health outcomes research该刊发表各开发阶段的临床研究，以及观察性、真实世界与健康结局研究。
• The remit covers the discovery, development and use of therapeutics and interventions, including devices, across all therapeutic areas其范围涵盖各治疗领域中治疗学与干预手段的发现、开发与应用，医疗器械亦包括在内。
• Studies relating to diagnostics, pharmacoeconomics, public health and epidemiology are encouraged与诊断、药物经济学、公共卫生及流行病学相关的研究受到鼓励。
• Quality of life, patient care, management and education are treated as part of the same remit, so the journal speaks to clinicians rather than to a narrow laboratory audience生活质量、患者照护、管理与教育被纳入同一范围，使该刊面向临床医生而非仅面向实验室听众。
• It publishes original research, reviews, communications and letters, and accepts positive, confirmatory and negative data alike该刊发表原创研究、综述、通讯与来信，正面、验证性与阴性数据均在接收之列。
• Submissions are welcomed whether they address an international audience or a country-specific one, which matters when a study targets a narrow patient population无论面向国际读者还是某一国家的读者，投稿均受欢迎，这对研究特定患者群体的课题尤为重要。
• It runs a rapid publication model with a peer review decision inside two weeks and online publication three to four weeks after acceptance, backed by an in-house editorial team该刊实行快速出版模式，两周内给出评审决定、录用后三至四周内在线发表，背后有专门的内部编辑团队支持。

History

• The journal was established in 1984 by Health Communications and has been published by Springer Healthcare since 2008该刊 1984 年由（Health Communications）创办，2008 年起由（Springer Healthcare）出版。
• It now sits within the Adis portfolio inside Springer Nature, the grouping that also carries the journal's other rapid clinical titles该刊现属（Springer Nature）旗下的（Adis）系列，与旗下其他快速临床刊物同列其中。
• It appears monthly, with volume 43 and issue 10 published in October 2026, a numbering consistent with a monthly schedule running since 1984该刊按月出版，2026 年 10 月为第 43 卷第 10 期，卷期编号与自 1984 年起的月刊节奏相符。
• It is published as a hybrid title, so subscription remains the default, but an open access option is offered for every article and those papers carry the Creative Commons Attribution-NonCommercial licence该刊采用混合出版模式，订阅仍为默认路径，但所有文章均提供开放获取选项，此类文章适用知识共享署名-非商业性使用许可（CC BY-NC）。
• Acceptance carries a mandatory Rapid Service Fee that buys the compressed schedule and the concierge service, and open access adds a further charge on top of it录用时须缴纳强制性的快速服务费，以此换取压缩后的出版周期与专人服务，选择开放获取则需在此基础上另行付费。
• Its 2025 Journal Impact Factor is 4.7 after 4.0 in 2024, the five-year figure is 4.6, the median time from submission to a first decision is 2 days, and downloads reached 3.5 million in 2025该刊 2025 年影响因子为 4.7，2024 年为 4.0，五年影响因子 4.6，从投稿到首次决定的中位时间为 2 天，2025 年下载量达 350 万次。

Editors

• Clare Shepherd serves as Managing Editor, and the journal is otherwise run by ten Section Editors who each carry a therapeutic area, among them Giustino Varrassi of the Fondazione Paolo Procacci in Rome for anesthesia and pain and Ian Menown of the Craigavon Cardiac Centre in Ireland for cardiology由（Clare Shepherd）担任执行编辑，此外设有十位分编辑各领一个治疗领域，其中罗马（Paolo Procacci 基金会）的（Giustino Varrassi）负责麻醉与疼痛，爱尔兰（Craigavon 心脏中心）的（Ian Menown）负责心血管。
• The remaining sections are diabetes and endocrinology, gastroenterology and hepatology, oncology, pharmacology and health economics and outcomes research, psychiatry, respiratory medicine, rheumatology and orthopedics, and urology其余板块为糖尿病与内分泌学、胃肠病学与肝病学、肿瘤学、药理学与卫生经济学及结局研究、精神病学、呼吸病学、风湿病学与骨科，以及泌尿学。
• Beneath them sits an editorial board divided into twenty-one sections, adding dermatology, genetics, hematology, infectious diseases, nephrology, neurology, obstetrics and gynecology, ophthalmology, surgery and a seat reserved for a patient advocate其下设编委会，分为二十一个板块，另设皮肤科、遗传学、血液学、传染病学、肾脏病学、神经病学、妇产科学、眼科学、外科学，并为患者倡导者保留席位。
• That board draws on clinicians from the United States, the United Kingdom, Italy, Japan, Canada, Argentina, Ireland, Slovakia and the Netherlands, with names such as Anthony H. Dickenson of University College London and Carlos Morillo of the University of Calgary该编委的临床医生来自美国、英国、意大利、日本、加拿大、阿根廷、爱尔兰、斯洛伐克与荷兰，其中有伦敦大学学院的（Anthony H. Dickenson）与卡尔加里大学的（Carlos Morillo）。
• Manuscripts are screened by the editorial team for fit and plagiarism before comprehensive single-blind peer review, at least two extended reviews are required, conflicting recommendations are referred to the editorial board, and appeals are considered case by case稿件先由编辑团队核查收录范围与重复率，随后进入全面单盲同行评审，一般至少需要两份详尽评审，意见相左时提交编委会裁定，申诉则逐案处理。
• Pre-submission enquiries are encouraged and a confidential assessment can be given, preprints on servers are welcome, and digital features such as plain language summaries and podcast articles are peer reviewed to the same standard as the article itself该刊鼓励投稿前咨询并可提供保密评估，欢迎在预印本平台发布预印本，通俗语言摘要与播客论文等数字内容与正文按同等标准送审。